Immuron Partners with Calmino to Enhance IBS Treatment Options
Immuron Teams Up with Calmino for ProIBS® Launch
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical leader based in Australia, has proudly announced an exclusive distribution agreement with Calmino Group AB for launching ProIBS® in Australia and New Zealand. This collaboration marks a significant milestone in the treatment of Irritable Bowel Syndrome (IBS), as Immuron aims to make ProIBS® widely available through retail pharmacy channels. With years of expertise in digestive health, Immuron is set to enrich its product lineup with this innovative solution.
Understanding Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) is a prevalent digestive disorder affecting a substantial portion of the population. It manifests symptoms such as abdominal discomfort, bloating, and unpredictable bowel movements. Approximately 30% of individuals experience IBS, and it tends to affect women more frequently than men. Various factors such as dietary choices and stress can influence the severity of symptoms, which can include chronic diarrhea or constipation.
The ProIBS® Advantage
ProIBS® stands out as a certified medical device specifically designed to alleviate IBS symptoms. Formulated with AVH200®, derived from Aloe barbadensis Miller, it effectively supports the intestinal mucosal barrier. This long-term treatment option has proven to be safe with no known interactions with other medications. In a usability study conducted with over 1,000 participants, 94% reported improvement in their symptoms, and an impressive 98% would recommend the product.
Executive Insights on the Collaboration
Flavio Palumbo, Chief Commercial Officer at Immuron, expressed excitement over this opportunity, stating that ProIBS® will complement their growing digestive health portfolio. The success of Travelan®, another product by Immuron, has paved the way for introducing ProIBS® as pharmacists will benefit from a compelling product that delivers results valued by customers. The product's recognition in European markets further enhances its credibility, as it has been available in Swedish pharmacies for a considerable time.
Collaboration Highlights
Tobias Kisker, CEO, and founder of Calmino Group AB, shared enthusiasm about this partnership, highlighting the potential that Australia and New Zealand represent in the Asia Pacific health market. Through their collaboration, both companies are committed to improving the quality of life for those suffering from IBS.
The Growing IBS Treatment Market
The IBS treatment market is projected to maintain a robust growth trajectory. Currently contributing to the broader Digestives & Intestinal Remedies market, it is estimated to reach significant revenues in the upcoming years, emphasizing the need for effective treatment solutions. Immuron is strategically poised to tap into this expanding market with ProIBS®.
About Immuron Limited
Immuron Limited (ASX: IMC; NASDAQ: IMRN) is dedicated to developing innovative biopharmaceutical solutions through oral delivery of targeted polyclonal antibodies aimed at treating inflammatory and infectious diseases. Their deep-rooted commitment to enhancing health outcomes is evident through their ongoing product development and market expansion.
Contact Information
Steven Lydeamore
Chief Executive Officer
Phone: +61 (0)3 9824 5254
Email: info@immuron.com
Frequently Asked Questions
What is ProIBS®?
ProIBS® is a certified medical device designed to treat symptoms of Irritable Bowel Syndrome, including abdominal pain and bloating.
Who is distributing ProIBS®?
Immuron Limited is exclusively distributing ProIBS® in Australia and New Zealand in partnership with Calmino Group AB.
What are the main symptoms of IBS?
Common symptoms of IBS include abdominal discomfort, bloating, and either chronic diarrhea or constipation.
How does AVH200® work in ProIBS®?
AVH200® supports the intestinal mucosal barrier and helps alleviate IBS symptoms effectively.
Who can benefit from using ProIBS®?
Individuals suffering from IBS symptoms, particularly those experiencing long-term discomfort, can benefit from using ProIBS®.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
